Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide Nasal Spray in Non-hospitalized COVID-19 Patients
NCT05599919Phase 3Completed
- Sponsor
- SaNOtize
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Nitric oxide patch (Fundación Cardiovascular de Colombia) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by SaNOtize. Primary endpoint: Efficacy of Nitric Oxide Nasal Spray combined with standard supportive care at 8 days. Started Nov 2021; status: completed.
02
Drugs
Nitric oxide patch (Fundación Cardiovascular de Colombia)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05599919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599919.